| Dr Steven M Weiss, MD | |
|
450 Clarkson Ave, Suite A, Brooklyn, NY 11203-2056 | |
| (718) 270-1432 | |
| (718) 270-4123 |
| Full Name | Dr Steven M Weiss |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 36 Years |
| Location | 450 Clarkson Ave, Brooklyn, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114912144 | NPI | - | NPPES |
| 01454911 | Medicaid | NY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | 185492-1 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mount Sinai South Nassau | Oceanside, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mount Sinai School Of Medicine | 6406096544 | 154 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
| Entity Name | South Nassau Family Medicine Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902891781 PECOS PAC ID: 4688563463 Enrollment ID: O20040311000216 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
| Entity Name | North Shore Medical Group Of The Mount Sinai School Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1275640609 PECOS PAC ID: 8921999087 Enrollment ID: O20040320000412 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
| Entity Name | University Physicians Of Brooklyn, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366506271 PECOS PAC ID: 0749192284 Enrollment ID: O20040401000120 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
| Entity Name | South Nassau Medical Group, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801153051 PECOS PAC ID: 9739335571 Enrollment ID: O20120809000411 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
| Entity Name | Mount Sinai School Of Medicine |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508127531 PECOS PAC ID: 6406096544 Enrollment ID: O20130712000368 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven M Weiss, MD 450 Clarkson Ave, Box 1262, Brooklyn, NY 11203-2056 Ph: (718) 270-8867 | Dr Steven M Weiss, MD 450 Clarkson Ave, Suite A, Brooklyn, NY 11203-2056 Ph: (718) 270-1432 |
News Archive
Plymouth University Peninsula Schools of Medicine and Dentistry will now become an active research and fundraising partner with Brain Tumour Research. The charity will support research and supply dedicated members of staff with expertise in fundraising, marketing and PR to work at both local and national levels alongside existing teams, creating a dynamic fundraising programme.
For the first time liposomes that imitate cells in the process of natural death have been used to treat Diabetes. Researchers at Germans Trias Research Institute (at UAB-Campus of International Excellence Sphere) generated liposomes in collaboration with professionals from the ICN2. PLOS ONE Journal publishes the work.
Sigma Tau Pharma Ltd. (hereinafter referred to as Sigma-Tau Rare Disease), today announced the submission of an application to the European Medicines Agency for use of its pegylatedL-asparaginase, Oncaspar (pegaspargase) for the treatment of Acute Lymphoblastic Leukaemia (ALL) as part of a multi-agent chemotherapeutic regimen.
Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has submitted a Phase II protocol to the U.S. Food and Drug Administration (FDA) for the clinical study of Serdaxin® for the treatment of Parkinson's disease (PD).
› Verified 4 days ago
Dr. Alexander Usorov, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 447 Atlantic Ave, Brooklyn, NY 11217 Phone: 718-858-6300 | |
Dr. Marcellus Andre Walker, MD Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 2094 Pitkin Ave, Brooklyn, NY 11207 Phone: 718-240-0516 Fax: 718-240-0564 | |
Lotus Ahmed, D.O Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 518 Mcdonald Ave, Brooklyn, NY 11218 Phone: 917-848-5432 Fax: 347-252-6754 | |
Mrs. Sophia Schwartzman, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 2700 Ocean Avenue, Brooklyn, NY 11229 Phone: 518-587-1141 | |
Dr. Haitham M Ahmed, MD, MPH Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 101 Pennsylvania Avenue, Brooklyn, NY 11207 Phone: 718-240-2000 Fax: 718-240-2260 | |
Yanjin Yang, Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-3000 | |
Ashwad Afzal, M.D. Infectious Disease Medicare: Medicare Enrolled Practice Location: 506 6th St, Brooklyn, NY 11215 Phone: 718-780-5246 |